

---

# Contents

## I. **Biology of Micrometastases and Advances in Methods for Detection**

The Biology of Melanoma Micrometastases . . . . .	3
<i>R. L. Barnhill</i>	
Disseminated Tumor Cells: Diagnosis, Prognostic Relevance, and Phenotyping . . . . .	14
<i>K. Pantel and M. Otte</i>	
Nested Quantitative Real Time PCR for Detection of Occult Tumor Cells . . . . .	25
<i>N. Max, K. Wolf, B. Spike, E. Thiel, and U. Keilholz</i>	
Detection of Micrometastasis Through Tissue-Specific Gene Expression: Its Promise and Problems . . . . .	32
<i>R. Jung, K. Soondrum, W. Krüger, and M. Neumaier</i>	
Immunobead-Based Detection and Characterization of Circulating Tumor Cells in Melanoma Patients . . . . .	40
<i>Ø. Fodstad, R. Faye, H.K. Høifødt, E. Skovlund, and S. Aamdal</i>	
Rapid Enrichment and Detection of Melanoma Cells from PBMC by a New Assay Combining Immunomagnetic Cell Sorting and Immunocytochemical Staining . . . . .	51
<i>C. Siewert, M. Herber, N. Hunzelmann, Ø. Fodstad, S. Miltenyi, M. Assenmacher, and J. Schmitz</i>	

## **II. Detection of Residual Melanoma Cells in the Peripheral Blood and Bone Marrow**

- Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) Detection  
of Melanoma-Related Transcripts in the Peripheral Blood  
and Bone Marrow of Patients with Malignant Melanoma.  
What Have We Learned? . . . . . 63  
*R. A. Ghossein, S. Bhattacharya, and D. G. Coit*
- The Clinical Utility of Multimarker RT-PCR in the Detection  
of Occult Metastasis in Patients with Melanoma . . . . . 78  
*B. Taback, D. L. Morton, S. J. O'Day, D.-H. Nguyen,  
T. Nakayama, and D. S. B. Hoon*
- Polymerase Chain Reaction in the Detection  
of Circulating Tumour Cells in Peripheral Blood  
of Melanoma Patients . . . . . 93  
*B. Schitteck, H.-J. Blaheta, U. Ellwanger, and C. Garbe*
- Facts and Pitfalls in the Detection of Tyrosinase mRNA  
in the Blood of Melanoma Patients by RT-PCR . . . . . 105  
*S. Seiter, G. Rapp, W. Tilgen, S. Ugurel, and U. Reinhold*
- Morphologically Intact Melanoma Cells May Be Detected  
in Peripheral Blood of Melanoma Patients . . . . . 113  
*A. Benez, U. Schiebel, and G. Fierlbeck*
- Prognosis of Metastatic Melanoma: No Correlation  
of Tyrosinase mRNA in Bone Marrow and Survival Time . . . . . 118  
*V. Waldmann, J. Wacker, M. Deichmann, A. Jäckel, M. Bock,  
and H. Näher*

## **III. Detection of Minimal Residual Disease in Sentinel Nodes**

- The Predictive Value of the Sentinel Lymph Node  
in Malignant Melanomas . . . . . 129  
*D. Bachter, C. Michl, H. Büchels, H. Vogt, and B. R. Balda*
- Detection of Micrometastasis in Sentinel Lymph Nodes of Patients  
with Primary Cutaneous Melanoma . . . . . 137  
*H.-J. Blaheta, B. Schitteck, H. Breuninger, and C. Garbe*

**IV. Early Recognition and Monitoring by Serological Markers**

Monitoring Malignant Melanoma with the S-100B Tumour Marker . 149  
*J.M.G. Bonfrer and C.M. Korse*

Melanoma Inhibitory Activity (MIA), a Serological Marker of Malignant Melanoma ..... 158  
*A.K. Bosserhoff, D. Dreau, R. Hein, M. Landthaler, W.D. Holder, and R. Buettner*

Quantification of Melanoma-Associated Molecules in Plasma/Serum of Melanoma Patients ..... 169  
*A. Hauschild, R. Gläser, and E. Christophers*

**V. Clinical Relevance of Micrometastases Detection**

Molecular Tools in the Detection of Micrometastatic Cancer Cells – Technical Aspects and Clinical Relevance ..... 181  
*M. von Knebel Doeberitz, J. Weitz, M. Koch, J. Lacroix, A. Schrödel, and C. Herfarth*

The Clinical Relevance of Molecular Staging for Melanoma ..... 187  
*S.C. Shivers, W. Li, J. Lin, A. Stall, M. Stafford, J. Messina, L.F. Glass, and D.S. Reintgen*

Clinical Significance of PCR-Positive mRNA Markers in Peripheral Blood and Regional Nodes of Malignant Melanoma Patients ..... 200  
*G. Palmieri, M. Pirastu, M. Strazzullo, P.A. Ascierto, S.M.R. Satriano, M.L. Motti, G. Botti, N. Mozzillo, G. Castello for the Melanoma Cooperative Group, A. Cossu, A. Lissia, and F. Tanda*

Decrease in Circulating Tumor Cells as an Early Marker of Therapy Effectiveness ..... 204  
*J.-C. Bystryrn, J. Albrecht, S.R. Reynolds, M.C. Rivas, R. Oratz, R.L. Shapiro, D.F. Roses, M.N. Harris, and A. Conrad*

**VI. Therapeutic Strategies  
Against Residual Melanoma Cells**

Utility of Tests for Circulating Melanoma Cells in Identifying Patients  
Who Develop Recurrent Melanoma . . . . . 211  
*B. J. Curry, K. Myers, and P. Hersey*

Active Specific Immunotherapy of Malignant Melanoma  
and Peptide Mimics of the Human High-Molecular-Weight  
Melanoma-Associated Antigen . . . . . 231  
*S. Ferrone and X. Wang*

Autologous Dendritic Cells for Treatment of Advanced Cancer –  
An Update . . . . . 236  
*D. Schadendorf and F. O. Nestle*

A Novel Strategy in the Elimination of Disseminated Melanoma Cells:  
Chimeric Receptors Endow T Cells with Tumor Specificity . . . . . 249  
*H. Abken, A. Hombach, C. Heuser, and U. Reinhold*

Subject Index . . . . . 265